Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239703 | 0.82 | NPC1 (0.61) | ADORA3TP53SLC29A1TDP1TSHR | |
| SCHEMBL27437734 | 0.80 | ADORA3 (0.76) | ADORA3TP53SLC29A1TDP1TSHR | |
| SCHEMBL13239708 | 0.80 | SLC29A1 (0.66) | SLC29A1 | |
| N6-Benzyladenosine SCHEMBL219438 | 0.80 | ADORA3 (1.00) | ADORA3TP53SLC29A1TDP1TSHR | |
| N6-Benzyladenosine SCHEMBL20419282 | 0.80 | ADORA3 (1.00) | ADORA3TP53SLC29A1TDP1TSHR | |
| N6-Benzyladenosine SCHEMBL23982413 | 0.80 | ADORA3 (1.00) | ADORA3TP53SLC29A1TDP1TSHR | |
| N6-Benzyladenosine SCHEMBL472635 | 0.80 | ADORA3 (1.00) | ADORA3TP53SLC29A1TDP1TSHR | |
| N6-Benzyladenosine SCHEMBL20419317 | 0.80 | ADORA3 (1.00) | ADORA3TP53SLC29A1TDP1TSHR | |
| N6-Benzyladenosine SCHEMBL472637 | 0.80 | ADORA3 (1.00) | ADORA3TP53SLC29A1TDP1TSHR | |
| N6-Benzyladenosine SCHEMBL13966412 | 0.80 | ADORA3 (1.00) | ADORA3TP53SLC29A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501931-B2 | Convertible nucleoside derivatives | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | LAKSHMAN MAHESH K | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179312-A1 | CONVERTIBLE NUCLEOSIDE DERIVATIVES | PNP, NUDT1, NUDT14 | ADORA3 138/4885TP53 4142/4885SLC29A1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.